6-K - BioLineRx Ltd. (0001498403) (Filer)

6-K - BioLineRx Ltd. (0001498403) (Filer)

424B5 - BioLineRx Ltd. (0001498403) (Filer)

6-K - BioLineRx Ltd. (0001498403) (Filer)

S-8 - BioLineRx Ltd. (0001498403) (Filer)

6-K - BioLineRx Ltd. (0001498403) (Filer)

6-K - BioLineRx Ltd. (0001498403) (Filer)

424B5 - BioLineRx Ltd. (0001498403) (Filer)

6-K - BioLineRx Ltd. (0001498403) (Filer)

6-K - BioLineRx Ltd. (0001498403) (Filer)

SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

TEL AVIV, Israel, Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 15 ordinary shares per ADS to 600 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-40 reverse stock split of the ADSs, reducing the number of outstanding ADSs from 142,340,133 to 3,558,503 ADSs. The ADSs will continue to trade on the Nasdaq C

TEL AVIV, Israel, Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) and accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS (or per ADS equivalent) and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.20 per share, will be exercisable immediatel

Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

- Executed license agreement with Ayrmid Ltd. for APHEXDA® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC - - Entered into agreement to reduce and restructure long-term debt by ~$16.5 million - - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA® (motixafortide) commercial program to Ayrmid - - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology - - Management to host conference call t

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC –  – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can

- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle -  - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including the initial results from a Phase

– Allowance strengthens company's intellectual property estate and extends motixafortide patent protection in the U.S. through December 2041 – TEL AVIV, Israel, Oct. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, titled, "COMPOSITION OF BL-8040," which covers the composition of motixafortide (APHEXDA®/BL-8040). The patent strengthens BioLineRx's robust intellectual property (IP) estate and extends its patent protection on motixafortide in the U.S. th

Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass., Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of Mobilization Matters, a digital resource for people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant. Launched on Apheresis Awareness Day, this platform offers patient stories, educational resources, and more to support those undergoing this critical phase of treatment.     In conjuncti

- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel, Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company purs

- Executed license agreement with Ayrmid Ltd. for APHEXDA® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC - - Entered into agreement to reduce and restructure long-term debt by ~$16.5 million - - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA® (motixafortide) commercial program to Ayrmid - - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology - - Management to host conference call t

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC –  – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can

- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel, Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company purs

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 8, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2024 on Thursday, August 15, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be ac

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 22, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2024 on Tuesday, May 28, 2024, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed thr

- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at targeted major transplant centers; received Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate Medicare reimbursement - - Announced first patient dosed in randomized Phase 2b clinical trial evaluating motixafortide in first-line pancreatic cancer - - Continued to support partner Gloria Biosciences in plans to execute pivotal bridging study of motixafortide in stem cell mobilization and Phase 2b randomized study in first-line pancreatic cancer in China - - Management to host conference call today, Mar

- Management to Hold Conference Call at 08:30 a.m. EDT - TEL AVIV, Israel, March 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open. The Company will host a conference call at 08:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed

- Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma - - Closed Exclusive License Agreement for Motixafortide in Asia Region with Concurrent Strategic Equity Investment - - Presented Encouraging Data at AACR from Pilot Phase of Randomized Phase 2 Combination Trial with Motixafortide in Patients with First Line PDAC - - Began Enrollment of Phase 1 Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease - - Management to host conference call today, November 20, at 10

- Management to Hold Conference Call at 10:00 a.m. EST - TEL AVIV, Israel, Nov. 13, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20, 2023, before the U.S. markets open. The Company will host a conference call at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be ac

Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.  Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions.  Her appointment is effective today, January 4, 2023. "Tami has tremendous experience across a range of therapeutic areas and drug development modalities," said Philip Serlin, Chief Executive Officer of BioLineRx. 

  - Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 career launches, including specific expertise in hematopoietic stem cell mobilization - TEL AVIV, Israel, June 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has appointed biopharmaceutical veteran executive Holly W. May as its Chief Commercial Officer. In this newly created role, based in the U.S., Ms. May will be responsible for the commercial planning, positioning and launch oversight for Motixafortide in the stem cell mobilization